Longitudinal Analysis of Plasma Proteomics Reveals Inflammatory and Immune Biomarkers Linked to Diagnosis and Treatment Response in Psoriasis After Secukinumab Administration - Top-Institutions - MDSpire

Longitudinal Analysis of Plasma Proteomics Reveals Inflammatory and Immune Biomarkers Linked to Diagnosis and Treatment Response in Psoriasis After Secukinumab Administration

  • By

  • Hongyang Zhang

  • Rui Yang

  • Yu Ma

  • Jiahui Yang

  • Binyan Yang

  • Lingdi Dong

  • Nan Yu

  • April 24, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Dermatology
    • Immunology
    • Proteomics

  • #2

    Harvard Medical School / Brigham and Women's Hospital
    Harvard Medical School / Brigham and Women's Hospital

    Boston, MA

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Research

  • #3

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Dermatology
    • Immunology
    • Proteomics

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Trials

  • #5

    University of Michigan Medical School
    University of Michigan Medical School

    Ann Arbor, MI

    Key Differentiators

    • Dermatology
    • Immunology
    • Proteomics

Original Source(s)

Longitudinal Analysis of Plasma Proteomics Reveals Inflammatory and Immune Biomarkers Linked to Diagnosis and Treatment Response in Psoriasis After Secukinumab Administration

  • by Hongyang Zhang, Rui Yang, Yu Ma, Jiahui Yang, Binyan Yang, Lingdi Dong, Nan Yu

  • April 24, 2026

Related Content

Dermatologic outcomes associated with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a large-scale target trial emulation

Inhibition of TYK2 in Skin Autoimmune Disorders: Achieving Remission of Discoid Lupus and Psoriasis with Deucravacitinib and Complementary Confocal Microscopy Evidence

Efficacy of Upadacitinib in Managing Coexisting Psoriasis and Lichen Planus: A Case Study